Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers

Open access

Published version of a preprint

Abstract

Background and aims: Two of the most lethal gastrointestinal (GI) cancers, gastric cancer (GC) and colon cancer (CC), are ranked in the top five cancers that cause deaths worldwide. Most GI cancer deaths can be reduced by earlier detection and more appropriate medical treatment. Unlike the current “gold standard” techniques, non-invasive and highly sensitive screening tests are required for GI cancer diagnosis. Here, we explored the potential of metabolomics for GI cancer detection and the classification of tissue-of-origin, and even the prognosis management. Methods: Plasma samples from 37 gastric cancer (GC), 17 colon cancer (CC), and 27 non-cancer (NC) patients were prepared for metabolomics and lipidomics analysis by three MS-based platforms. Univariate, multivariate, and clustering analyses were used for selecting significant metabolic features. ROC curve analysis was based on a series of different binary classifications as well as the true-positive rate (sensitivity) and the false-positive rate (1-specificity). Results: GI cancers exhibited obvious metabolic perturbation compared with benign diseases. The differentiated metabolites of gastric cancer (GC) and colon cancer (CC) were targeted to same pathways but with different degrees of cellular metabolism reprogramming. The cancer-specific metabolites distinguished the malignant and benign, and classified the cancer types. We also applied this test to before- and after-surgery samples, wherein surgical resection significantly altered the blood-metabolic patterns. There were 15 metabolites significantly altered in GC and CC patients who underwent surgical treatment, and partly returned to normal conditions. Conclusion: Blood-based metabolomics analysis is an efficient strategy for GI cancer screening, especially for malignant and benign diagnoses. The cancer-specific metabolic patterns process the potential for classifying tissue-of-origin in multi-cancer screening. Besides, the circulating metabolites for prognosis management of GI cancer is a promising area of research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11306-023-02002-0

Cites

0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 MS-based metabolomics and performance. A Workflow of the MS-based metabolomics. More details are described in a previous study (Shi et al., 2022). B Stacked chart of the metabolic features from the LC–MS polar, LC–MS lipid, and GC–MS platforms. The features of LC–MS platforms were obtained using both positive and negative ionization modes. Orange: annotated metabolites; Blue: unknown features
Fig. 1 MS-based metabolomics and performance. A Workflow of the MS-based metabolomics. More details are described in a previous study (Shi et al., 2022). B Stacked chart of the metabolic features from the LC–MS polar, LC–MS lipid, and GC–MS platforms. The features of LC–MS platforms were obtained using both positive and negative ionization modes. Orange: annotated metabolites; Blue: unknown featuresCC BY · PubMed Central
Fig. 2 Metabolomic differentiation of gastric and colon cancer samples compared with non-cancer samples. A Heatmap of metabolites that differed between the cancer and non-cancer groups (Source data_1). Cluster method: weighted. The obviously changed metabolite clusters are highlighted in the three black dashed boxes. B Venn diagram of significantly changed metabolites of GC and CC samples compared with NC. |Log2(foldchange)|> 0.25, p value < 0.05 (Source data_2). C Pathway enrichment analysis of significantly changed metabolites in a comparison of the GC and CC groups with the NC group. Visualization was constructed using MetaboAnalyst 5.0 (https://www.metaboanalyst.ca/). GC: gastric cancer; CC: colon cancer; NC: non-cancer
Fig. 2 Metabolomic differentiation of gastric and colon cancer samples compared with non-cancer samples. A Heatmap of metabolites that differed between the cancer and non-cancer groups (Source data_1). Cluster method: weighted. The obviously changed metabolite clusters are highlighted in the three black dashed boxes. B Venn diagram of significantly changed metabolites of GC and CC samples compared with NC. |Log2(foldchange)|> 0.25, p value < 0.05 (Source data_2). C Pathway enrichment analysis of significantly changed metabolites in a comparison of the GC and CC groups with the NC group. Visualization was constructed using MetaboAnalyst 5.0 (https://www.metaboanalyst.ca/). GC: gastric cancer; CC: colon cancer; NC: non-cancerCC BY · PubMed Central
Fig. 3 ROC curve analysis of metabolites in the different groups. ROC curve analysis of differential metabolites between (A) groups GC and NC, (B) groups CC and NC, and (C) groups GC and CC. The analyzed metabolites included dexamethasone, TAG 53:0, TAG 57:5, (9Z)-5,8,11-trihydroxy-9-octadecenoic acid, and PE 34:1; PE 34:2, hydrocortisone, hypoxanthine, PE 36:4, and PE 34:3; and PE 40:8e, PE 40:3, PE 36:1p, PC 42:1, and (2α, 3α, 5ξ, 9ξ)-2,3-dihydroxyurs-12-en-28-oic acid. GC: gastric cancer; CC: colon cancer; NC: non-cancer. The ROC curves were based on a series of different binary classifications (demarcation value or determination threshold) as well as the true-positive rate (sensitivity) and the false-positive rate (1-specificity)
Fig. 3 ROC curve analysis of metabolites in the different groups. ROC curve analysis of differential metabolites between (A) groups GC and NC, (B) groups CC and NC, and (C) groups GC and CC. The analyzed metabolites included dexamethasone, TAG 53:0, TAG 57:5, (9Z)-5,8,11-trihydroxy-9-octadecenoic acid, and PE 34:1; PE 34:2, hydrocortisone, hypoxanthine, PE 36:4, and PE 34:3; and PE 40:8e, PE 40:3, PE 36:1p, PC 42:1, and (2α, 3α, 5ξ, 9ξ)-2,3-dihydroxyurs-12-en-28-oic acid. GC: gastric cancer; CC: colon cancer; NC: non-cancer. The ROC curves were based on a series of different binary classifications (demarcation value or determination threshold) as well as the true-positive rate (sensitivity) and the false-positive rate (1-specificity)CC BY · PubMed Central
Fig. 4 Metabolic differences before and after surgery in gastric and colon cancers from identical subjects. A PCA of metabolic profiles. Identical subjects are indicated using red connecting lines with the time interval (days). B Heatmap of the top 50 metabolites (Source data_3). Blue: before surgery; Orange: after surgery. GC: gastric cancer; CC: colon cancer; BS: before surgery; AS: after surgery
Fig. 4 Metabolic differences before and after surgery in gastric and colon cancers from identical subjects. A PCA of metabolic profiles. Identical subjects are indicated using red connecting lines with the time interval (days). B Heatmap of the top 50 metabolites (Source data_3). Blue: before surgery; Orange: after surgery. GC: gastric cancer; CC: colon cancer; BS: before surgery; AS: after surgeryCC BY · PubMed Central
Fig. 5 Differentiated metabolites before and after surgery. Box plots of significantly changed metabolites after the surgery of GC (A) and CC (B) patients and compared with NC control. |Log2(foldchange)|> 0.25, p value < 0.05. (*) indicates the significant difference between post-surgery and NC control, p value < 0.05. y axis: scaled intensity. Blue: before surgery (BS); Orange: after surgery (AS); GC: gastric cancer; CC: colon cancer; NC: non-cancer patient control. Source data are provided as Source data_4
Fig. 5 Differentiated metabolites before and after surgery. Box plots of significantly changed metabolites after the surgery of GC (A) and CC (B) patients and compared with NC control. |Log2(foldchange)|> 0.25, p value < 0.05. (*) indicates the significant difference between post-surgery and NC control, p value < 0.05. y axis: scaled intensity. Blue: before surgery (BS); Orange: after surgery (AS); GC: gastric cancer; CC: colon cancer; NC: non-cancer patient control. Source data are provided as Source data_4CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 25

Metadata

Authors
Song, G., Wang, L., Tang, J., Li, H., Pang, S., Li, Y., Liu, L., & Hu, J.
Affiliations
Second Hospital of Tianjin Medical University (CN)
Corresponding author
  • Liu, Li
  • Hu, Junyuan
Venue
Metabolomics
Published
2023-04-04
Volume
19
Issue
4
Pages
36-36
ISSN
  • 1573-3882 (ISSN-L)
  • 1573-3890
OpenAlex
W4362523860
Cited by
25
References
60
Citations by year
2026: 7 · 2025: 9 · 2024: 9
FWCI
2.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Metabolomics (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Physical Sciences › Engineering › Biomedical Engineering › Advanced Chemical Sensor Technologies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
circulating metabolites, biomarkers, gastrointestinal cancer, gastric cancer, colon cancer, cancer screening, early detection, prognosis, plasma metabolomics, lipidomics, surgical resection
MeSH terms
Colonic Neoplasms, Gastrointestinal Neoplasms, Humans, Prognosis, Stomach Neoplasms, Biomarkers, Tumor, Metabolomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers. https://app.cochat.ai/papers/10.1007/s11306-023-02002-0
The paper
Song, G., Wang, L., Tang, J., Li, H., Pang, S., Li, Y., Liu, L., & Hu, J. (2023). Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers. Metabolomics. https://doi.org/10.1007/s11306-023-02002-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.